⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 3, 2024Expert Opinion on Drug Safety

Signal mining and gender differences analysis of adverse events in NMIBC treatment with gemcitabine and BCG bladder instillation based on the FAERS database

Ben Wang Er-hao Bao Binglei Jiang Lin Yang Ying Liu Long Xia Jia-Hao Wang Li Wang Ping-Yu Zhu

View at Publisher

Ask AI

Bookmark

Share

Abstract

To explore safety differences and perform a gender-based analysis of adverse events related to gemcitabine and Bacillus Calmette-Guérin (BCG) vaccine using the U.S. FDA Adverse Event Reporting System (FAERS) database.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wang et al. (2024) studied this question.

synapsesocial.com/papers/68e5d8bab6db64358756ecc2 https://doi.org/10.1080/14740338.2024.2388212

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Comparison of Long-Term Oncological Outcomes of Intravesical Bacillus Calmette–Guérin Versus Gemcitabine in Treatment-Naïve Non-Muscle-Invasive Bladder Cancer with Intermediate and High Risk: A Multicenter Retrospective AnalysisCohort Study · 2026
2Abstract B007: Urinary cytokine profiles reflect rationale for treatment with gemcitabine and Bacillus Calmette-Guérin (BCG) in BCG-exposed high-risk non-muscle invasive bladder cancer (NMIBC)2024
3Abstract PR005: Final results from a Phase I trial of intravesical chemoimmunotherapy with gemcitabine and Bacillus Calmette-Guérin (BCG) for patients with BCG-exposed high-grade non-muscle invasive bladder cancer2024 · 2 citations
4Gemcitabine-Based Bladder Preservation in BCG-Unresponsive High-Risk NMIBC: Evidence, Limitations, and Clinical PositioningCohort Study · 2026
5Efficacy and Toxicity in Scheduled Intravesical Gemcitabine Versus Bacillus Calmette–Guérin for Bladder Cancer: A Systematic Review and Meta-AnalysisMeta-Analysis · 2026

More related papers

Gemcitabine versus Bacillus Calmette-Guérin (BCG) in Non Muscle Invasive Transitional Cell Carcinoma of the Bladder after Trans-Urethral Resection2024
The GAIN trial: Gemcitabine alternating with intravesical BCG randomized against BCG alone for patients with recurrent “BCG-exposed” high-grade non-muscle invasive bladder cancer (NMIBC) (ALLIANCE A032303).2026
A Phase I Clinical Trial of Chemoimmunotherapy with Alternating Intravesical Gemcitabine and Bacillus Calmette-Guérin (GemBCG) for BCG-Exposed High-Grade Non-Muscle-Invasive Bladder Cancer2026

More from Expert Opinion on Drug Safety

Long-term safety of treatment of hemophilia A: a comprehensive reviewTue,
Tolerance of methotrexate co-administered with pegloticase in patients with uncontrolled gout: overview of the findings from the mirror RCTWed,